GCP
LXEO icon

GSA Capital Partners’s Lexeo Therapeutics LXEO Stock Holding History

GSA Capital Partners’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-34,269
Closed -$197K – 1985
2026
Q1 		$197K Buy
34,269
+22,806
+199% +$162K 0.01% 1464
2025
Q4 		$114K Buy
+11,463
New +$105K 0.01% 1515
2025
Q3 		– Sell
-14,528
Closed -$58K – 1911
2025
Q2 		$58K Buy
+14,528
New +$47.8K ﹤0.01% 1654

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

GSA Capital Partners's LXEO Position: Q2 2026 in Review

GSA Capital Partners sold out of Lexeo Therapeutics (LXEO) in Q2 2026, closing a stake of 34,269 shares — an estimated $197K sold.

GSA Capital Partners first reported a position in LXEO in Q2 2025 and held it in 3 quarters. The position peaked at $197K in Q1 2026. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • GSA Capital Partners reported no remaining Lexeo Therapeutics position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 34,269 Lexeo Therapeutics shares in Q2 2026, an estimated $197K.
  • GSA Capital Partners first reported a position in Lexeo Therapeutics in Q2 2025 and held it in 3 quarters.
  • GSA Capital Partners's Lexeo Therapeutics position peaked at $197K in Q1 2026.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.